Tumour cell lysate-loaded dendritic cell vaccine induces biochemical and memory immune response in castration-resistant prostate cancer patients

D. Reyes, L. Salazar, E. Espinoza, C. Pereda, E. Castellón, R. Valdevenito, C. Huidobro, M. Inés Becker, A. Lladser, M. N. López, F. Salazar-Onfray

Resultado de la investigación: Contribución a una revistaArtículo

39 Citas (Scopus)

Resumen

Background:Recently, we produced a tumour antigen-presenting cells (TAPCells) vaccine using a melanoma cell lysate, called TRIMEL, as an antigen source and an activation factor. Tumour antigen-presenting cells induced immunological responses and increased melanoma patient survival. Herein, we investigated the effect of TAPCells loaded with prostate cancer cell lysates (PCCL) as an antigen source, and TRIMEL as a dendritic cell (DC) activation factor; which were co-injected with the Concholepas concholepas haemocyanin (CCH) as an adjuvant on castration-resistant prostate cancer (CRPC) patients.Methods:The lysate mix capacity, for inducing T-cell activation, was analysed by flow cytometry and Elispot. Delayed-type hypersensitivity (DTH) reaction against PCCL, frequency of CD8 + memory T cells (Tm) in blood and prostate-specific antigen (PSA) levels in serum were measured in treated patients.Results:The lysate mix induced functional mature DCs that were capable of activating PCCL-specific T cells. No relevant adverse reactions were observed. Six out of 14 patients showed a significant decrease in levels of PSA. DTH + patients showed a prolonged PSA doubling-time after treatment. Expansion of functional central and effector CD8 + Tm were detected.Conclusion:Treatment of CRPC patients with lysate-loaded TAPCells and CCH as an adjuvant is safe: generating biochemical and memory immune responses. However, the limited number of cases requires confirmation in a phase II clinical trial.

Idioma originalInglés
Páginas (desde-hasta)1488-1497
Número de páginas10
PublicaciónBritish Journal of Cancer
Volumen109
N.º6
DOI
EstadoPublicada - 17 sep 2013

Áreas temáticas de ASJC Scopus

  • Oncología
  • Investigación sobre el cáncer

Huella Profundice en los temas de investigación de 'Tumour cell lysate-loaded dendritic cell vaccine induces biochemical and memory immune response in castration-resistant prostate cancer patients'. En conjunto forman una huella única.

  • Citar esto

    Reyes, D., Salazar, L., Espinoza, E., Pereda, C., Castellón, E., Valdevenito, R., Huidobro, C., Inés Becker, M., Lladser, A., López, M. N., & Salazar-Onfray, F. (2013). Tumour cell lysate-loaded dendritic cell vaccine induces biochemical and memory immune response in castration-resistant prostate cancer patients. British Journal of Cancer, 109(6), 1488-1497. https://doi.org/10.1038/bjc.2013.494